» Articles » PMID: 23953350

Lifetime Direct Medical Costs of Treating Type 2 Diabetes and Diabetic Complications

Overview
Journal Am J Prev Med
Specialty Public Health
Date 2013 Aug 20
PMID 23953350
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lifetime direct medical cost of treating type 2 diabetes and diabetic complications in the U.S. is unknown.

Purpose: This study provides nationally representative estimates of lifetime direct medical costs of treating type 2 diabetes and diabetic complications in people newly diagnosed with type 2 diabetes, by gender and by age at diagnosis.

Methods: A type 2 diabetes simulation model was used to simulate the disease progression and direct medical costs among a cohort of newly diagnosed type 2 diabetes patients. The study sample used for the simulation was based on data from the 2009-2010 National Health and Nutritional Examination Survey. The costs of treating type 2 diabetes and diabetic complications were derived from published literature. Annual medical costs were accumulated over the life span of type 2 diabetes to determine the lifetime medical costs. All costs were calculated from a healthcare system perspective, and expressed in 2012 dollars.

Results: In men diagnosed with type 2 diabetes at ages 25-44 years, 45-54 years, 55-64 years, and ≥ 65 years, the lifetime direct medical costs of treating type 2 diabetes and diabetic complications were $124,700, $106,200, $84,000, and $54,700, respectively. In women, the costs were $130,800, $110,400, $85,500, and $56,600, respectively. The age-gender weighted average of the lifetime medical costs was $85,200, of which 53% was due to treating diabetic complications. The cost of managing macrovascular complications accounted for 57% of the total complication cost.

Conclusions: Over the lifetime, type 2 diabetes imposes a substantial economic burden on healthcare systems. Effective interventions that prevent or delay type 2 diabetes and diabetic complications might result in substantial long-term savings in healthcare costs.

Citing Articles

The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.

Aranishi T, Igarashi A, Hara K, Osumili B, Cai Z, Mizogaki A Diabetes Ther. 2024; 16(3):431-445.

PMID: 39708085 PMC: 11868005. DOI: 10.1007/s13300-024-01675-7.


The impact of site-specific DNA methylation in promoter on type 2 diabetes.

Zhu M, Huang Q, Li H, Zhao Y, Guo H, Wang T Heliyon. 2024; 10(22):e39934.

PMID: 39584094 PMC: 11585805. DOI: 10.1016/j.heliyon.2024.e39934.


Combined Diabetes Education/Skills Training and Social Needs Resolution Intervention for Older African Americans with Poorly Controlled Type 2 Diabetes (DM Social Needs): Study Protocol for a Randomized Controlled Trial.

Dawson A, Walker R, Davidson T, Knapp R, Egede L Healthcare (Basel). 2024; 12(19).

PMID: 39408171 PMC: 11475830. DOI: 10.3390/healthcare12191991.


Association of lipid-lowering drugs with the risk of type 2 diabetes and its complications: a mendelian randomized study.

Zhang Y, Chen B, Wan Q Diabetol Metab Syndr. 2024; 16(1):240.

PMID: 39367514 PMC: 11451088. DOI: 10.1186/s13098-024-01477-8.


Healthy lifestyle associated with dynamic progression of type 2 diabetes: A multi-state analysis of a prospective cohort.

Ma Y, Chen Y, Ge A, Long G, Yao M, Shi Y J Glob Health. 2024; 14:04195.

PMID: 39327893 PMC: 11427933. DOI: 10.7189/jogh.14.04195.